Company intelligence / Profile preview
ProtAffin
Graz, Styria, Austria
- Ownership
- Private
- Development stage
- Other
01
Overview
ProtAffin developed engineered chemokines as GAG antagonists with anti-inflammatory activity. Lead product PA401, based on a modified interleukin‑8, showed preclinical efficacy in models of acute and chronic inflammation and entered a Phase 1 trial for inflammatory lung disease. The company also reported preclinical data for an MCP‑1 decoy program in multiple sclerosis models. No further clinical results are available after early-stage trials.
- Therapeutic areas
- ImmunologyNeurologyPulmonology
- Modalities
- ProteinRecombinant proteinEngineered chemokine (protein-based glycosaminoglycan antagonist)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed.
Beyond the preview
Go deeper on ProtAffin.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProtAffin.